List view / Grid view
The DMC recommendation was made following a planned analysis of…
10 December 2013 | By Merck
The DMC recommendation was made following a planned analysis of interim safety data that included a safety cohort of 200 patients treated with MK-8931 for at least 3 months...
Merck provides update on Phase III clinical program for preladenant,…
23 May 2013 | By Merck
Merck provides update on Phase III clinical program for preladenant, the company’s investigational parkinson’s disease medicine...
ZIOPTAN™ (tafluprost ophthalmic solution) 0.0015%, the first preservative-free prostaglandin analog…
13 February 2012 | By Merck
ZIOPTAN™ (tafluprost ophthalmic solution) 0.0015%, the first preservative-free prostaglandin analog ophthalmic solution...
